Suggestions
Ariel Gordon
Entrepreneur. Startup Founder, Angel investor , Strategic & Startup advisor
Ariel Gordon is a prominent figure in the biotechnology sector, serving as a co-founder and investor at NeuroSense Therapeutics, a company focused on developing treatments for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS). His involvement in NeuroSense stems from personal experiences, as his wife suffers from ALS, motivating him to seek effective therapies for this debilitating condition.
Background and Career
Ariel Gordon's journey into the biotech field was significantly influenced by the challenges faced by his family due to ALS. Alongside Yossi Gross, he co-founded NeuroSense Therapeutics in 2016, driven by a shared commitment to finding a cure for ALS after witnessing the impact of the disease on loved ones.23 Gordon's role involves not just investment but also active participation in the company's research initiatives, particularly in screening potential therapeutic molecules.1
Contributions to NeuroSense Therapeutics
At NeuroSense, Gordon has been instrumental in the development of PrimeC, a promising treatment that combines two molecules targeting key pathways involved in ALS progression. The company is currently concluding a Phase 2b clinical trial with encouraging results.1 Gordon's background as an entrepreneur and his personal connection to ALS have positioned him as a passionate advocate for innovative solutions in this field.
Vision and Future Goals
Gordon envisions expanding NeuroSense's efforts beyond ALS to include treatments for other neurodegenerative diseases like Alzheimer’s and Parkinson’s. He emphasizes the importance of resilience and creativity in overcoming the significant challenges faced in drug development. His ultimate goal is to bring effective therapies to market that can significantly improve the quality of life for patients suffering from these conditions.12
Through his work at NeuroSense Therapeutics, Ariel Gordon exemplifies how personal experiences can drive professional endeavors aimed at making a meaningful impact on healthcare.
Highlights
Alon Ben-Noon 🇮🇱 wow Alon the PP per protocol e.g participants who participated in the PIIB trial according to the protocols are Fantastic 37% improment and now with a strong p=0.03 statistical outcome !!!! Wow this proves to me the that we can impact and help many ALS patients live longer and better 😊. Good luck with the next steps.
Alon Ben-Noon 🇮🇱 and team , I would like to congratulate you on the positive and exciting outcome of the PIIb clinical trial. 29% improvement in the ALSFrs score in a non hetrognios population is something which if I remember correctly no drug achieved. Looking forward to the biomarker outcomes and PIII #ALS IsrALS Niva Russek- Blum NeuroSense Therapeutics ALS TDI
